K. Kunii

发表

Small molecule activation of PKM2 in cancer cells induces serine auxotrophy.

L. Cantley, C. Kung, J. Hixon, 2012, Chemistry & biology.

Cancer-Associated SF3B1 Hotspot Mutations Induce Cryptic 3' Splice Site Selection through Use of a Different Branch Point.

M. Warmuth, Shouyong Peng, K. Kunii, 2015, Cell reports.

MTAP Deletions in Cancer Create Vulnerability to Targeting of the MAT2A/PRMT5/RIOK1 Axis.

A. Kernytsky, S. Choe, K. Marks, 2016, Cell reports.

Involvement of the serotonergic system in orexin-induced behavioral alterations in rats

K. Kunii, T. Sakurai, M. Yanagisawa, 2002, Regulatory Peptides.

A role for iNOS in fasting hyperglycemia and impaired insulin signaling in the liver of obese diabetic mice.

K. Kunii, K. Ueki, M. Kaneki, 2005, Diabetes.

Orexin-mediated feeding behavior involves both leptin-sensitive and -insensitive pathways

A. Yamanaka, K. Kunii, T. Sakurai, 2002, Physiology & Behavior.

Selective pharmaceutical inhibition of PARP14 mitigates allergen-induced IgE and mucus overproduction in a mouse model of pulmonary allergic response

Kevin C. Chen, M. Niepel, K. Swinger, 2021, bioRxiv.

Type II Phosphatidylinositol 4-Kinase β Is a Cytosolic and Peripheral Membrane Protein That Is Recruited to the Plasma Membrane and Activated by Rac-GTP*

K. Kunii, P. Włodarski, B. Barylko, 2002, The Journal of Biological Chemistry.

PARP7 negatively regulates the type I interferon response in cancer cells and its inhibition triggers antitumor immunity.

Tim J. Wigle, M. Niepel, K. Swinger, 2021, Cancer cell.

H3B-8800, an Orally Bioavailable Modulator of the SF3b Complex, Shows Efficacy in Spliceosome-Mutant Myeloid Malignancies

M. Warmuth, O. Abdel-Wahab, B. Caleb, 2016 .

Abstract #1751: MK-8033, a selective c-Met / Ron inhibitor, suppresses tumor cell growth in vitro and in vivo

P. Majumder, W. Lu, K. Kunii, 2009 .

Discovery of a 5H-benzo[4,5]cyclohepta[1,2-b]pyridin-5-one (MK-2461) inhibitor of c-Met kinase for the treatment of cancer.

K. Kunii, M. Altman, A. Szewczak, 2011, Journal of medicinal chemistry.

PARP14 inhibition restores PD-1 immune checkpoint inhibitor response following IFNγ-driven adaptive resistance

M. Niepel, K. Kunii, B. Telfer, 2022, bioRxiv.

An Inhibitor of Mutant IDH1 Delays Growth and Promotes Differentiation of Glioma Cells

Fang Wang, Timothy A. Chan, Evangelia Komisopoulou, 2013, Science.

FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival.

Cem Elbi, K. Kunii, A. Di Bacco, 2008, Cancer research.

PDK1 attenuation fails to prevent tumor formation in PTEN-deficient transgenic mouse models.

K. Kunii, R. Bronson, M. Scott, 2011, Cancer research.

Therapeutics , Targets , and Chemical Biology PDK 1 Attenuation Fails to Prevent Tumor Formation in PTEN-Deficient Transgenic Mouse Models

Hare, K. Kunii, R. Bronson, 2011 .

Discovery of the First Potent Inhibitors of Mutant IDH1 That Lower Tumor 2-HG in Vivo.

S. Gross, Shunqi Yan, J. Saunders, 2012, ACS medicinal chemistry letters.

Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis

Christian M. Metallo, William J. Israelsen, Abhishek K. Jha, 2012, Nature chemical biology.

Evidence of mTOR Activation by an AKT-Independent Mechanism Provides Support for the Combined Treatment of PTEN-Deficient Prostate Tumors with mTOR and AKT Inhibitors.

C. Paweletz, P. Majumder, K. Kunii, 2012, Translational oncology.

MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor.

C. Paweletz, K. Kunii, I. Kariv, 2010, Cancer research.

FGFR 2-Amplified Gastric Cancer Cell Lines Require FGFR 2 and Erbb 3 Signaling for Growth and Survival

K. Kunii, M. Yashiro, H. Hatch, 2008 .

456 SF3B1 mutations induce disease relevant aberrant mRNA splicing in cancer and confer sensitivity to spliceosome inhibition

M. Warmuth, K. Kunii, D. Aird, 2014 .

A potent and selective PARP14 inhibitor decreases protumor macrophage gene expression and elicits inflammatory responses in tumor explants.

M. Niepel, K. Swinger, K. Kunii, 2021, Cell chemical biology.

Orexins/hypocretins regulate drinking behaviour 1 Published on the World Wide Web on 4 August 1999. 1

A. Yamanaka, K. Kunii, T. Sakurai, 1999, Brain Research.

Down‐regulation of the Notch pathway mediated by a γ‐secretase inhibitor induces anti‐tumour effects in mouse models of T‐cell leukaemia

C. Kenific, K. Kunii, J. Hardwick, 2009, British journal of pharmacology.

Orexin-induced food intake involves neuropeptide Y pathway

A. Yamanaka, K. Kunii, T. Sakurai, 2000, Brain Research.

Erratum: Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis (Nature Chemical Biology (2012) 8 (839-847))

Abhishek K. Jha, G. Stephanopoulos, Noel Southall, 2012 .

RESEARCH PAPER Down-regulation of the Notch pathway mediated by a g-secretase inhibitor induces anti-tumour effects in mouse models of T-cell leukaemia

P. Majumder, C. Kenific, K. Kunii, 2009 .

Tissue-engineered skin using aggregates of normal human skin fibroblasts and biodegradable material

Y. Sakai, K. Kunii, K. Furukawa, 2001, Journal of Artificial Organs.

Effects of hormone and growth factor on formation of fibroblast-aggregates for tissue-engineered skin

Y. Sakai, K. Kunii, K. Furukawa, 2001 .

Differentiation of Glioma Cells An Inhibitor of Mutant IDH 1 Delays Growth and Promotes

A. Kernytsky, C. Brennan, T. Graeber, 2013 .

Abstract 1344: Small molecule inhibitor of CD38 modulates its intra- and extracellular functions leading to antitumor activity

M. Niepel, K. Kunii, V. Richon, 2021, Experimental and Molecular Therapeutics.

Abstract 2932: SF3B1 mutations induce aberrant mRNA splicing in cancer and confer sensitivity to spliceosome inhibition

M. Warmuth, K. Kunii, J. Feala, 2014 .

Cancer-Associated Mutations in SF3B1 Exhibit Neomorphic Splicing Activity and Block Erythroid Differentiation

B. Ebert, M. Warmuth, K. Kunii, 2014 .

MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor.

C. Paweletz, K. Kunii, I. Kariv, 2010, Cancer research.